Novocure (NASDAQ: NVCR), a Swiss firm renowned for its pioneering Tumor Treating Fields (TTFields) cancer therapy, has received marketing approval from the US Food and Drug Administration (FDA) for its Optune Lua device. This portable device is now cleared for use in combination with PD-1/PD-L1 inhibitors or docetaxel to treat adult patients with metastatic non-small cell lung cancer (mNSCLC) who have experienced disease progression on or after a platinum-based chemotherapy regimen.
Optune Lua generates alternating electric fields, or TTFields, which are delivered through non-invasive, wearable arrays placed on the skin. These fields apply physical forces to the electrically charged components of dividing cancer cells, leading to cancer cell death while sparing healthy cells. The technology represents a significant advancement in the non-invasive treatment of cancer.
Novocure’s strategic partnership with China’s Zai Lab Ltd (HKG: 9688), established in 2018, has been instrumental in expanding the reach of TTFields therapy. In 2020, Zai Lab secured approval for the TTFields product in the treatment of glioblastoma (GBM), marking a milestone in the application of this innovative technology in oncology.- Flcube.com
